Atreca, Inc. (BCEL)
| Market Cap | 3.60M |
| Revenue (ttm) | 263,000 |
| Net Income (ttm) | -95.08M |
| Shares Out | 39.98M |
| EPS (ttm) | -2.43 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 66,253 |
| Open | 0.0901 |
| Previous Close | 0.0930 |
| Day's Range | 0.0901 - 0.0985 |
| 52-Week Range | 0.0520 - 1.2640 |
| Beta | 1.02 |
| Analysts | Hold |
| Price Target | 1.00 (+1,009.88%) |
| Earnings Date | May 8, 2024 |
About BCEL
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozo... [Read more]
Financial Performance
In 2022, Atreca's revenue was $770,000, a decrease of -9.52% compared to the previous year's $851,000. Losses were -$90.53 million, -17.20% less than in 2021.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for BCEL stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 1,009.88% from the latest price.
News
BCEL Stock Alert: Halper Sadeh LLC Is Investigating Atreca, Inc.
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether Atreca, Inc.'s (NASDAQ: BCEL) definitive asset purchase agreement with Immunome, Inc. to sell a colle...
Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome
CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platfo...
Immunome to Acquire Antibody-Related Assets and Materials from Atreca
SEATTLE & EXTON, Pa.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that it ...
Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives
SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Atreca Announces Agreement to Terminate Lease and Departure of Chief Financial Officer Herb Cross
SAN CARLOS, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
Atreca Reports Second Quarter 2023 Financial Results and Announces Corporate Restructuring
Suspending development of ATRC-101 Cost-saving measures include 40% workforce reduction Focusing on advancing earlier stage ADC candidates and preserving discovery capabilities SAN CARLOS, Calif., Aug...
Atreca Presents Data from Ongoing Phase 1b Study of ATRC-101 in Patients with Select Advanced Solid Tumors during Oral Abstract Session at the ASCO 2023 Annual Meeting
Clinical activity observed in multiple tumor types; longer progression-free survival observed in patients with high target expression; ATRC-101 continues to be well-tolerated
Atreca Reports First Quarter 2023 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
Atreca Announces Oral Presentation of ATRC-101 Phase 1b Study Data at ASCO 2023 Annual Meeting
SAN CARLOS, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel cancer therapeutics generated through a ...
Atreca to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference
SAN CARLOS, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
Atreca Reports Fourth Quarter and Full-Year 2022 Financial Results and ATRC-101 Data Update
ATRC-101 continues to be well tolerated in ongoing Phase 1b trial; clinical activity observed in multiple tumor types; longer progression free survival observed in patients with high target expression
Atreca to Host Fourth Quarter and Year End 2022 Conference Call and Webcast on March 29, 2023
Call/webcast to feature updates on the discovery platform and pipeline, including updated data from the ongoing Phase 1b trial of ATRC-101 Call/webcast to feature updates on the discovery platform and...
Atreca to Participate at Cowen's 43rd Annual Health Care Conference
SAN CARLOS, Calif., March 01, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...
Atreca and Xencor to Develop T Cell Engaging Bispecific Antibody Directed Against Novel Solid Tumor Target
SAN CARLOS, Calif., and MONROVIA, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics genera...
Atreca Appoints Philippe Bishop, MD as Chief Medical Officer
SAN CARLOS, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Atreca Reports Third Quarter 2022 Financial Results and Provides Pipeline Update
SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on ...
Atreca to Present at Upcoming Investor Conferences
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Atreca Announces Poster Presentations at Society for Immunotherapy of Cancer (SITC) Annual Meeting
SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Atreca Reports Second Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #AI--Cellino Announces Appointment of Abhijit Kulkarni, Ph.D. as Chief Operating Officer and Paulette Dillon as Chief Business Officer
Atreca Appoints Stephen Gould, Ph.D. as Chief Scientific Officer
SAN CARLOS, Calif., June 16, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique d...
Atreca Announces Corporate Reorganization to Extend Cash Runway
Company continuing to advance ATRC-101, ATRC-301 and other oncology pipeline assets
Atreca Reports First Quarter 2022 Financial Results and Recent Corporate Developments
SAN CARLOS, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
Atreca Announces Publication in PNAS: “Mobilization of Innate and Adaptive Antitumor Immune Responses by the RNP-Targeting Antibody ATRC-101”
SAN CARLOS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique di...
Atreca to Present at Upcoming Virtual Investor Conferences
SAN CARLOS, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique ...